The judicious use of immunostains can be of significant diagnostic assistance in the interpretation of testicular neoplasms when the light microscopic features are ambiguous. A limited differential diagnosis by traditional morphology is required for the effective use of immunohistochemistry (IHC); otherwise, the inevitable occurrence of exceptions to anticipated patterns will lead to "immunoconfusion." The diagnosis of tumors in the germ cell lineage, the great majority of primary tumors of the testis, has been considerably facilitated over the past decade by IHC directed at developmentally important nuclear transcription factors, including OCT4, SALL4, SOX2, and SOX17, that are mostly restricted to certain tumor histotypes. In conjunction with other markers, a specific diagnosis can be achieved in most instances through a panel of 3 or 4 immunostains and often fewer. IHC among tumors in the sex cord-stromal group may produce a significant proportion of false-negative cases until more sensitive and equally specific markers are validated. The negativity of these tumors for the IHC stains used for germ cell tumors is key in the important distinction of neoplasms in these 2 general categories. In this review, the International Society of Urological Pathologists (ISUP) provides diagnostic guidelines in the form of algorithms to assist practicing pathologists confronting a differential diagnostic question concerning a testicular neoplasm. The goal of ISUP is to anticipate commonly encountered differential diagnoses and recommend an efficient and limited pattern of IHC stains to resolve the question.
T esticular neoplasms are the most frequent solid malignancy in young men, and yet, compared with other forms of cancer, they are relatively uncommon. Many diagnostic pathologists, therefore, have little experience with them, and often utilize immunohistochemical markers to assist with diagnosis. Immunohistochemical studies can be very helpful in resolving difficult differential considerations among testicular tumors, but their application should always be targeted on the basis of a careful light microscopic analysis of standard hematoxylin and eosin-stained tissue sections. The light microscopic features of these neoplasms remain the "gold standard," and it is only when these features are ambiguous that immunohistochemistry plays a significant role. Overall, <5% of testicular neoplasms should require immunostaining for accurate interpretation.
There are recurring differential diagnostic situations in testicular neoplasia, and directed immunohistochemistry can resolve between a discrete number of diagnostic possibilities. Pathologists must remember, however, that exceptions to expected immunoreactivities are invariable and that the clinical, serological, and light microscopic features of any given case represent the crucial context for the interpretation of any staining results.
THE DIFFERENTIAL DIAGNOSIS OF GERM CELL TUMORS
The great majority (approximately 95%) of primary testicular tumors is of germ cell origin, 1 and these require accurate subtyping for proper management. When a tumor is recognized as of germ cell type, particularly because of its association with the unclassified form of intratubular germ cell neoplasia (IGCNU), 2 a diagnostic algorithm (Table 1) can be applied that helps resolve among various entities. Limited portions of this algorithm may be applied to specific differential diagnoses under consideration. A broad, nontargeted approach is discouraged.
OCT4 (also known as OCT3/4 or POU5F1) serves a "gatekeeper" function in the germ cell tumor subtyping algorithm. It is a nuclear protein that is essential for the maintenance of pluripotency in embryonic stem cells. On the basis of nuclear reactivity, it divides the various entities into 2 groups--embryonal carcinoma and seminoma (both positive) or yolk sac tumor, spermatocytic seminoma, and choriocarcinoma (all negative). It is virtually 100% sensitive for embryonal carcinoma and seminoma and also uniformly positive in IGCNU. [3] [4] [5] [6] [7] All other testicular tumors are negative. Most other neoplasms of nontesticular origin are also negative, 4 although there are rare instances of OCT4 positivity in non-small cell carcinoma of the lung, clear cell carcinoma of the kidney, and large B-cell lymphoma. It has no value if the differential diagnosis does not involve entities in the 2 separate groups of germ cell tumors (Table 1) . Occasional cases of embryonal carcinoma may lose OCT4 reactivity following chemotherapy. 8 It is important that only nuclear staining be regarded as positive.
A common and clinically important differential diagnosis based on morphology and positive reactivity for OCT4 is the distinction of seminoma from embryonal carcinoma. Antibodies to several antigens are useful in this context, and a 2-stain panel with opposite patterns of reactivity is recommended (Table 1) . CD117, a tyrosine kinase receptor expressed on stem cells, can be demonstrated in 95% to 100% of seminomas (as well as IG-CNU) as cytoplasmic membrane reactivity (Fig. 1) , but almost all embryonal carcinomas are negative, and there is variable reactivity for it in yolk sac tumors and spermatocytic seminomas as well. [9] [10] [11] [12] [13] [14] [15] [16] One useful alternative to CD117 is podoplanin, a transmembrane mucoprotein expressed on fetal germ cells, lymphatic endothelium, and mesothelium. Almost all seminomas (and cases of IG-CNU) express podoplanin on the cytoplasmic membranes, whereas embryonal carcinomas are either negative or, in about 30% of the cases, show limited reactivity that is restricted to the apical surfaces of the cells. 13, [17] [18] [19] [20] A second alternative to CD117 is SOX17 (SRY-box 17), a member of the SOX family of nuclear transcription factors involved in embryonic development. Nuclear reactivity for SOX17 occurs in about 95% of seminomas and 50% of yolk sac tumors but is absent in embryonal carcinomas. 14, 21, 22 The differential diagnosis of seminoma from embryonal carcinoma should be further validated by immunostaining for another antigen that characteristically has an opposite pattern of reactivity to CD117, podoplanin, and SOX17. CD30 is a preferred choice in this context. It is a member of the tumor necrosis factor receptor family and has a cytoplasmic membrane and Golgi apparatus distribution. Positive reactivity occurs in 93% to 100% of embryonal carcinomas, but the other germ cell tumors, including seminoma, are either negative or show only rare positive cells (Fig. 2) . 5, 12, 14, [23] [24] [25] [26] [27] As is the case for OCT4, positive staining for CD30 may be lost after chemotherapy. 8, 28 AE1/AE3 antibody is a useful alternative choice. This anticytokeratin cocktail has broad specificity for a number of cytokeratin subtypes (1 to 8, 10, 14 to 16, and 19) and is positive in the tumor cell cytoplasm of all nonseminomatous germ cell tumors. The majority of seminomas are nonreactive, although 20% to 36% may show some degree of staining that is mostly paranuclear and dotlike. 23, 25, 29 AE1/AE3 also highlights the trophoblast cells that may occur in some seminomas, and these cells are insufficient for classification as a nonseminomatous tumor. SOX2 (SRY-box 2) is another alternative to CD30. It is a member of the SOX family of nuclear transcription factors involved in embryonic development and specifically plays a role in maintenance of pluripotency in undifferentiated embryonic stem cells. SOX2 is positive in 96% of embryonal carcinomas and <1% of seminomas. 14, 21, 22, 25, 30 It is also negative in yolk sac tumors, choriocarcinomas, and IGCNU but stains non-neoplastic Sertoli cells. 14, 21, 22, 25, 30 It likely will become a preferred marker for the distinction of seminoma from embryonal carcinoma, but it is currently a technically difficult stain. Yolk sac tumor, spermatocytic seminoma, and choriocarcinoma are all negative for OCT4, a property that serves to distinguish them from seminoma and embryonal carcinoma (Fig. 3) . They can be distinguished from one another with the use of other immunohistochemical markers (Table 1) . Glypican 3 (GPC3) is a membrane-anchored heparin sulfate that is demonstrable in all yolk sac tumors ( Fig. 4 ) and in 80% of choriocarcinomas. [31] [32] [33] It is rare in embryonal carcinomas (5%) and absent in seminomas, including spermatocytic seminoma. Occasional gastric carcinomas and many hepatocellular carcinomas also react for GPC3. 34, 35 Additional support for yolk sac tumor may be achieved by positivity for a-fetoprotein (AFP), a major plasma protein produced by the yolk sac and liver during fetal life. About 85% of yolk sac tumors are AFP positive but often only focally so, which stands in contrast to GPC3, which typically has diffuse tumor reactivity. 29, [36] [37] [38] Like GPC3, it is frequently positive in hepatocellular carcinomas and hepatoid carcinomas of other organs and sometimes in a variety of other carcinomas. The other germ cell tumors, except for occasional glands of teratomas, are negative for AFP. Support for choriocarcinoma derives from reactivity for human chorionic gonadotrophic (hCG), a dimeric glycoprotein that is produced by placental trophoblast cells, chiefly the syncytiotrophoblasts. It shares the same a chain with several pituitary hormones, including thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone. The b chain is unique to hCG and hence the preferred antigenic marker for it. Essentially all choriocarcinomas are positive for bhCG, but such reactivity is often limited to syncytiotrophoblasts or intermediate trophoblasts, 29, 36, 39 so if these are scant (a situation that commonly occurs following chemotherapy) bhCG reactivity may be limited. In addition, a sizable number of non-germ cell carcinomas of visceral origin, most commonly lung, urinary bladder, and gastrointestinal carcinomas, may demonstrate trophoblastic differentiation with concomitant hCG reactivity and elevated serum hCG, 40 a finding therefore that is not necessarily indicative of a germ cell tumor. Other forms of germ cell tumor apart from choriocarcinoma often have associated trophoblast cells, so hCG reactivity in isolation should not be considered indicative of choriocarcinoma but must be viewed in context of the light microscopic morphology. Placental alkaline phosphatase, an allosteric enzyme found in placental trophoblasts, may also play a limited role in this differential diagnosis as it is positive in approximately 50% of yolk sac tumors and choriocarcinomas and is negative in spermatocytic seminomas, a neoplasm that is mostly negative for the commonly used germ cell tumor markers with the exception of CD117. 15, 29, 41 
ISUP Recommendations
A general approach to the subtyping of germ cell tumors can be achieved therefore by a limited panel consisting of antibodies directed against OCT4, CD117, CD30, and GPC3, although this may be further reduced if the light microscopic morphology is also limited to a more restricted differential. For instance, the differential diagnosis of seminoma versus embryonal carcinoma could be effectively evaluated in most cases by a 2-stain panel of CD117 and CD30.
THE DIFFERENTIAL DIAGNOSIS OF SEX CORD-STROMAL TUMOR AND GERM CELL TUMOR
Although light microscopy is sufficient to distinguish most tumors in the sex cord-stromal group from germ cell tumors, there are occasional cases that are problematic. This is most apt to occur with those unusual Sertoli cell tumors having a predominantly diffuse growth of pale cells that may also be accompanied by a lymphocytic infiltrate, in which both seminoma and solid yolk sac tumor may be brought to mind. 42 In addition, some Sertoli cell tumors may grow in a prominently corded or trabecular pattern that calls to mind reticular yolk sac tumor (Fig. 5) . In this circumstance, SALL4 is a very effective discriminator between the sex cord-stromal tumors and those germ cell tumors that are realistic considerations in this context (Table 2 ). SALL4 is a zinc finger nuclear transcription factor that plays a role in embryonic development, including maintenance of pluripotency of embryonic stem cells. It appears to work in concert with other pluripotency-related nuclear transcription factors including OCT4 and NANOG. It is expressed in 100% of seminomas, embryonal carcinomas, and yolk sac tumors; 69% of choriocarcinomas; and 52% of teratomas. [43] [44] [45] The sex cord-stromal tumors are SALL4 negative. 45 Additional support for a sex cord-stromal tumor (Table 2 ) apart from SALL4 negativity can also be obtained from immunostains directly against a-inhibin and calretinin. Inhibin is a dimeric glycoprotein in the transforming growth factor b superfamily that inhibits the production and secretion of gonadotropins from the pituitary gland. Antibodies to the a-subunit stain a variable number of sex cord-stromal tumors of the testis, with Leydig cell tumors showing close to 100% reactivity but Sertoli cell tumors showing positivity rates of 30% to 91% in different studies (Fig. 5) . 42, [46] [47] [48] [49] [50] Syncytiotrophoblast cells are positive, but other elements of germ cell tumors are negative. 48, 49, 51 Nontesticular tumors may also stain for a-inhibin, including adrenal cortical neoplasms, hemangioblastomas, some clear cell renal cell carcinomas, and rare soft tissue tumors. [52] [53] [54] Currently, a-inhibin is considered the single best marker for sex cord-stromal tumors of the testis. Calretinin, a calcium binding protein of the E-F hand protein family, has a similar staining profile as a-inhibin for the sex cord-stromal tumors; almost all Leydig cell tumors are positive, but only a minority of Sertoli cell tumors is positive. 55 The germ cell tumors are negative. Numerous other tumor types, however, may also stain for calretinin. 56 Preliminary work suggests that steroidogenic factor 1 may be FIGURE 5 . A, The cord-like growth of this Sertoli cell tumor caused concern for reticular yolk sac tumor, but the (B) patchy reactivity for a-inhibin supported the former diagnosis. 
ISUP Recommendations
A reasonable and efficient panel for the differential diagnosis of sex cord-stromal tumor versus germ cell tumor, therefore, consists of SALL4, a-inhibin, and calretinin. In a laboratory lacking SALL4, an alternative, although somewhat more complex, algorithm can be devised to assist with this differential diagnosis (Table 3) using a panel of OCT4, GPC3, a-inhibin, and calretinin.
THE DIFFERENTIAL DIAGNOSIS OF LYMPHOMA AND GERM CELL TUMOR
An important differential diagnosis is the distinction of a germ cell tumor from large cell lymphoma. Seminoma is the tumor most apt to be misinterpreted as lymphoma because of its tendency for intertubular growth and the occasional plasmacytoid appearance of its cells. Infrequent lymphomas have features reminiscent of embryonal carcinoma because of prominent intratubular growth and a degree of tumor cohesion. These 2 features have been most notable in lymphomas of anaplastic large cell type and natural killer/T-cell type. [57] [58] [59] [60] [61] [62] [63] A useful algorithm to assist with the differential diagnosis of germ cell tumor versus large cell lymphoma (Table 4 ) involves a panel of SALL4 and specific lymphoid markers but especially those that are reactive in neoplastic B cells, which represent the great majority of large cell lymphomas found in the testis. [64] [65] [66] [67] An important caveat concerning the algorithm is the occasional reactivity for SALL4 in lymphoblastic lymphomas, anaplastic large cell lymphomas, and myeloid leukemias, 68 so confirmation of a SALL4-positive tumor as a germ cell tumor should be performed using select markers from algorithm 1 ( Table 1) . Again, if the laboratory does not have SALL4 available, an alternative approach can be used (Table 5) .
ISUP Recommendations
An efficient initial panel for the differential diagnosis of germ cell tumor and large cell lymphoma of the testis, therefore, consists of SALL4, CD45, CD20, and CD3 or, in the absence of SALL4, consists of OCT4, GPC3, AE1/AE3, CD45, CD20, and CD3.
THE DIFFERENTIAL DIAGNOSIS OF METASTATIC CARCINOMA AND GERM CELL TUMOR
Metastases of high-grade carcinomas to the testis, although generally recognizable as such on the basis of light microscopic criteria and clinical context, may occasionally cause concern for a germ cell tumor, usually seminoma, embryonal carcinoma, or yolk sac tumor. In this circumstance, and even more so when there is a tumor at a metastatic site and one is dealing with limited biopsy material, immunohistochemical studies are helpful (Table 6 ). SALL4 is positive in those germ cell tumors that are apt to have morphologic overlap with metastatic carcinoma, and it is usually negative but occasionally positive in high-grade carcinomas, which have been found to be positive in 20% to 30% of cases of urothelial carcinoma, gastric adenocarcinoma, high-grade serous carcinoma of the ovary, small cell carcinoma of the lung, and undifferentiated carcinoma. 69 A negative study for SALL4 expression therefore provides strong support for a tumor other than a germ cell tumor if the internal controls (non-neoplastic germ cells in the testis) are reactive. Epithelial membrane antigen (EMA), a glycoprotein found in the membranes of milk fat globules, is also valuable in this context as it is positive in most carcinomas and in some sarcomas and anaplastic large cell lymphomas and is mostly negative in seminomas (2% positive), yolk sac tumors (2% positive), and embryonal carcinomas (2% to 12% positive). 23, 29 If the specific differential diagnosis involves metastatic carcinoma and yolk sac tumor, cytokeratin 7, a type II keratin of simple, nonkeratinizing epithelium, is useful because of its positive reactivity in most adenocarcinomas (with the notable exceptions of prostate, kidney, and colon carcinomas) and negativity in yolk sac tumor. 70, 71 
ISUP Recommendations
An efficient and concise initial immunohistochemical panel for the differential diagnosis of germ cell tumor versus high-grade carcinoma consists of SALL4, OCT4, and EMA or, alternatively, OCT4, GPC3, EMA, and CK7 (Table 7) . If the diagnosis of metastatic carcinoma is supported, more specific markers may next be used in an effort to pinpoint the primary site.
THE DIFFERENTIAL DIAGNOSIS OF CHORIOCARCINOMA AND SEMINOMA WITH SYNCYTIOTROPHOBLAST CELLS
If a seminoma develops numerous syncytiotrophoblast cells with associated microhemorrhages, there may be concern for a biphasic pattern of choriocarcinoma. The distinction of these 2 possibilities largely depends upon the nature of the associated mononucleated cell population, whether seminoma cells or trophoblast cells. This distinction can be accomplished with OCT4, which is uniformly positive in seminoma cells and negative in trophoblast cells. 4, 5, 45 SOX17 is an alternative choice (Table 8 ). 14, 22 It is important to distinguish neoplastic intratubular germ cells (IGCNU) from either reactive or atypical germ cells other than IGCNU because of the uniform progression of IGCNU to an invasive germ cell tumor and the unknown natural history of other forms of atypical germ cells. 72 In this situation, OCT4 is the preferred marker because of its uniform sensitivity for IGCNU and the fact that it is only rarely positive in other germ cells--notably in those with delayed maturation, a situation mostly encountered in the gonads of patients with disorders of sex development and that may also be rarely encountered in young children with cryptorchidism (Table 9 ). 4, 6, [73] [74] [75] [76] Placental alkaline phosphatase and podoplanin are good alternative choices with a similar immunoreactivity profile, although the sensitivity of placental alkaline phosphatase for IGCNU is slightly less than the other 2, with reports of 83% to 100% positivity. [77] [78] [79] [80] [81] [82] [83] We do not recommend CD117, SALL4, or SOX17 because of their staining of non-neoplastic germ cells. 
